Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study).
Most patients with atrial fibrillation are at risk of suffering thromboembolic events. This risk can be reduced by twothirds by efficient anticoagulation. This prospective multi-center trial investigated whether the quality of treatment can be improved by self-management in patients with atrial fibrillations (SMAAF Study) compared to conventional patient management by the family doctor.


METHODS
Two thousand patients suitable for self-management were to be randomized into the two arms of the study. In the period of investigation from December 1999 to July 2001, only 202 patients (64.3+/-9.2 years, 69.3% men) consented to participate. The study was discontinued prematurely since the number of patients was too low. As a consequence, the group comparison is confined to the evaluation of the INR values measured using the two-tailed t test.


RESULTS
Of the 202 patients included, 101 were assigned to the self-management group (64.6+/-9.6 years, 71.4% men) and 101 (64.1+/-8.9 years, 61.4% men, n.s.) were assigned to the group managed by the family doctor. The total number of INR measurements was 2 865. This comprised 2 072 measurements in patients under self-management and 793 in the family doctor group. The values were within the target range significantly more frequently (p=0.0061) in patients under self-management (67.8%) as compared to the family doctor group (58.5%). There was a trend with regard to the time within target range, but the difference was not significant (178.8+/-126 days as compared to 155.9+/-118.4 days). In the self-management group, there were two severe hemorrhages, and there was one thromboembolic event in the family doctor group.


CONCLUSIONS
Management of oral anticoagulation by INR self-management in patients with atrial fibrillation is not inferior to conventional care.
Völler
H
H
Klinik am See, Fachklinik für Innere Medizin, Kardiologie, Seebad 84, 15562 Rüdersdorf/Berlin, Germany. heinz.voeller@klinikamsee.com
Glatz
J
J
Taborski
U
U
Bernardo
A
A
Dovifat
C
C
Heidinger
K
K
D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005194:Family Practice; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data; D011446:Prospective Studies; D012648:Self Care; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*
D000925:Anticoagulants